Navigation Links
Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer
Date:6/14/2010

Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood. In his article in the June 10, 2010 New England Journal of Medicine, "Recent Advances in Neuroblastoma," Maris reviews the field's latest research knowledgemuch of it based on efforts by Maris and his colleagues at The Children's Hospital of Philadelphia. Maris directs a laboratory at CHOP in collaboration with the multicenter Children's Oncology Group (COG) using tissue samples from 5,000 patientsthe world's largest sample collection for neuroblastoma.

A cancer of the sympathetic nervous system, neuroblastoma most commonly occurs as a solid tumor arising from the adrenal gland in the abdomen. Neuroblastoma remains one of the most puzzling of childhood cancersranging from cases of widespread but benign tumors in infants that spontaneously and completely disappear, to high-risk subtypes in older children that are relentlessly aggressive.

Maris is the chief of Oncology at Children's Hospital and director of the Hospital's Center for Childhood Cancer Research. Just three years ago, he wrote a review article on neuroblastoma for The Lancet. Since that time, a stream of discoveries from his lab has explored the genetic landscape of neuroblastoma. In 2008, Maris led the team that identified common DNA variations on chromosome 6, the first time researchers found the cancer's genetic origin. Later that year, Yael Mosse, M.D., collaborating at CHOP with Maris, reported that mutations in the ALK gene were the main cause of inherited neuroblastoma, and also played a role in many cases of non-inherited neuroblastoma. In 2009, Maris published two more gene studies, identifying common variants in the gene BARD1 and copy number variants on chromosome 1 that raised the risk of neuroblastoma. The latter study was the first ever to find a specific copy number variant that predisposes to a human cancer.

The ultimate goal of basic research at CHOP is to translate findings into more effective treatments for children. To that end, the Cancer Center at CHOP is currently leading a clinical trial of an ALK inhibitor for children who have relapsed after neuroblastoma treatments. In his review, Maris describes other innovative therapies, such as a national immunotherapy trial by the COG, using monoclonal antibodies and cytokines to selectively target neuroblastoma cells. Another experimental treatment, developed at CHOP and other centers, uses MIBG, a radioactive isotope that zeroes in on neuroblastoma cells. Maris also cites federally sponsored collaborative programs designed to identify new drugs that will interrupt the key cell signaling pathways that drive neuroblastoma.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert  

Related medicine news :

1. Sanford Heart Hospital Physicians Again Recognized Internationally for Innovative Techniques
2. Northern California Cancer Centers Findings on Breast Cancer and Secondhand Smoke Released Internationally by the American Association for Cancer Research
3. Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area
4. American Red Cross Responds Internationally and at Home to Chile Quake
5. Dr. Mahaveer Mehta, A Well Known Dermatologist from Dubai, Receives Prestigious 'Hind Rattan Award'
6. Major Imaging Initiative to Shed Light on Little Known Brain Disease
7. Physicians Coalition Asks Federal Court to Block Obama Healthcare: Doctors Claim Bill Would End Practice of Medicine as We Have Known It, Assert Presidents Actions Are Unconstitutional
8. Yoga reduces cytokine levels known to promote inflammation
9. Penn researchers find genetic link to leukemias with an unknown origin
10. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
11. Chiropractic Traffic CEO Matt Prados Releases the Easiest and Fastest Free Chiropractic Marketing Method Known to Man
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Internationally known neuroblastoma expert reviews progress versus challenging childhood cancer
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... ... crisis. Her son James, eight, was out of control. Prone to extreme mood shifts and ... him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife on ... say he was going to kill them. If we were driving on the freeway, ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
Breaking Medicine Technology: